Insider trade

Director purchased ~$100K of BSX shares in the open market

Traded Aug 5, 2026 · Filed Aug 7, 2026

~$100K
Reported value · 2,100 sh @ $47.589: 17K
Holds after · shares reported: -9.4%
stock since the trade · S&P 500 -0.8%, $47.74 → $43.23 on Oct 1

Why it stands out

A board member of Boston Scientific spent $100K of their very own money to buy Boston Scientific shares. 3 other people at Boston Scientific bought some too, in the same month. Their pile of Boston Scientific shares grew by 14%.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 5, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 7, 2026

Director$25K–$100KHoldings +14%4 insiders bought in 30d

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$99,937

Shares × reported transaction price

Size band

$25K–$100K

Ownership change

+13.9%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

First purchase in 0 months

Confirmed open-market purchases by the same insider in the available history

Largest by this insider

No

Compared with 4 earlier confirmed purchases

Cluster activity

4 distinct insiders in 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Timing vs results

7 days after results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $47.74 on Aug 5, 2026, 12% above its 52-week low and 56% below its high, after a 5% rise over the previous 30 trading days

52-week range $42.63 (Jul 14, 2026) to $108.14 (Sep 8, 2025), 8% of the way up, from 251 adjusted closes. 30 trading days earlier: $45.60 on Jun 23, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Mar 5, 2026 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

2 such cases were open. In re: Boston Scientific Corporation Securities Litigation, docket 1:26-cv-40075, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+1.9%	-0.1%	+2.0%
30 days	-10.9%	-1.4%	-9.5%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-26-007031
Filed / recorded: Aug 7, 2026, 8:16 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: BOSTON SCIENTIFIC CORP
Issuer CIK: 885725
Ticker: BSX
Reporting person: David C Habiger
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Aug 5, 2026
Transaction code: P
Shares / units: 2,100
Price per share: $47.589
Acquired / disposed: Acquired (A)
Shares owned after: 17,160
Ownership form: Direct
Amendment: No

Footnotes from the filing

Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $47.21 to $47.98, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Around the same time

5w ago

1,171Shares

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

5w ago

567Shares · @ $48.37

Routine share withholding; mechanical by default.

Why it stands out Official record

5w ago

1,171Derivative units

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record